Posts in the “Treatment Options Treatment Options” category:

Therapy treats lung cancer based on patients’ genetic markers

Posted by Gianna Nannini on October 28th, 2014 |

SF Gate – October 28, 2014 – A new type of clinical trial for lung cancer patients getting under way at hospitals in the Bay Area and around the country may change the way drugs are tested in the future. That’s a pretty bold expectation, but researchers say the study — called the Lung Cancer… Read More

Advancing the development of new “targeted drug therapies” by enhancing the science of biomarkers

Posted by Samantha Powell on October 3rd, 2014 |

A key area of new drug development lies in the field of targeted therapies, sometimes called “personalized medicines,” which are drugs tailored to the genetic makeup of individual patients. These drugs are called targeted therapy because health care professionals can use clinical test results from a patient to select a specific drug that has a… Read More

Bristol Myers Squibb Getting Close To Lung Cancer Approval For Nivolumab

Posted by Samantha Powell on October 2nd, 2014 |

Bristol-Myers Squibb recently announced key developments regarding its immuno-oncology drug nivolumab. The FDA in the U.S. has granted breakthrough status to the drug for advanced melanoma and has agreed to review the license application on priority basis. The review is likely to be completed by the end of March 2015. Additionally, the EMA (European Medicines… Read More

AstraZeneca Whale Racing With Minnow to Develop Lung Cancer Drug

Posted by Samantha Powell on October 1st, 2014 |

The race to develop a new class of lung-cancer medicines is pitting one of the world’s biggest drugmakers against a five-year-old startup. AstraZeneca Plc (AZN), the U.K.’s second-largest pharmaceutical company, and Clovis Oncology Inc. (CLVS) of Boulder, Colorado, both intend to seek approval from regulators next year. Both drugs, which target a form of the… Read More

Bristol-Myers’ oncology star lines up for lung cancer approval, leading the PD-1 pack

Posted by Samantha Powell on September 29th, 2014 |

Among the scrum of drugmakers racing forward with a new class of cancer treatments, Bristol-Myers Squibb ($BMY) was the first to win a global regulatory nod and is now first in line for approval in lung cancer, a particularly lucrative indication for the group of promising oncology drugs. The company has completed a European application… Read More

CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer

Posted by Samantha Powell on September 29th, 2014 |

CytRx Corporation CYTR, -0.36% a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted multiple Orphan Drug Designations for the Company’s lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer. Aldoxorubicin is CytRx’s modified version of… Read More

Conventional Surgery May Trump Radiosurgery for Some Early Lung Cancers

Posted by Samantha Powell on September 25th, 2014 |

Despite having a higher rate of early complications, patients with non-small cell lung cancer (NSCLC) did better in the long run with conventional surgery than with radiotherapy to remove their cancer, a finding that supports the current practice of treating healthier patients with surgery instead of radiosurgery. In this study from Yale University using Medicare… Read More

Stanford licenses promising cancer drug to local biotech startup

Posted by Samantha Powell on September 25th, 2014 |

Most cancer patients don’t die because of a single tumor, but rather multiple tumors that spread throughout the body. A new therapy, developed by Stanford University researchers and licensed by a local biotech startup, appears to disrupt the deadly process known as metastasis, which causes cancer cells to break away from the original tumor sites… Read More

Curcumin spice linked to slowing of lung lining cancer

Posted by Samantha Powell on September 22nd, 2014 |

A new study has revealed that Asian spice Curcumin show promise in slowing the progression of mesothelioma, a cancer of the lung’s lining often linked to asbestos. According to the study by scientists from Case Western Reserve University and the Georg-Speyer-Haus in Frankfurt, Germany, the spice which is a derivative of the spice turmeric and… Read More

Dye offers hope for removal of all traces of tumors

Posted by Samantha Powell on September 21st, 2014 |

A third of patients who undergo surgery to remove cancerous tumors end up with microscopic pieces left behind. These overlooked remnants can lead to the recurrence of cancer after what was thought to be a successful surgery. Two surgeons at the University of Pennsylvania have joined forces to try to solve this problem. Their solution:… Read More